Correlation Between Lipella Pharmaceuticals and HCW Biologics

Can any of the company-specific risk be diversified away by investing in both Lipella Pharmaceuticals and HCW Biologics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lipella Pharmaceuticals and HCW Biologics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Lipella Pharmaceuticals Common and HCW Biologics, you can compare the effects of market volatilities on Lipella Pharmaceuticals and HCW Biologics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lipella Pharmaceuticals with a short position of HCW Biologics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lipella Pharmaceuticals and HCW Biologics.

Diversification Opportunities for Lipella Pharmaceuticals and HCW Biologics

-0.18

Correlation Coefficient

Lipella Pharmaceuticals  HCW Biologics

Good diversification

The 3 months correlation between Lipella and HCW is -0.18. Overlapping area represents the amount of risk that can be diversified away by holding Lipella Pharmaceuticals Common and HCW Biologics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on HCW Biologics and Lipella Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lipella Pharmaceuticals Common are associated (or correlated) with HCW Biologics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of HCW Biologics has no effect on the direction of Lipella Pharmaceuticals i.e., Lipella Pharmaceuticals and HCW Biologics go up and down completely randomly.

Pair Corralation between Lipella Pharmaceuticals and HCW Biologics

Given the investment horizon of 90 days Lipella Pharmaceuticals is expected to generate 17.97 times less return on investment than HCW Biologics. But when comparing it to its historical volatility, Lipella Pharmaceuticals Common is 5.3 times less risky than HCW Biologics. It trades about 0.02 of its potential returns per unit of risk. HCW Biologics is currently generating about 0.08 of returns per unit of risk over similar time horizon. If you would invest  42.00  in HCW Biologics on September 3, 2024 and sell it today you would earn a total of  5.00  from holding HCW Biologics or generate 11.9% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Lipella Pharmaceuticals Common  vs.  HCW Biologics

Lipella Pharmaceuticals

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Lipella Pharmaceuticals Common are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent basic indicators, Lipella Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in January 2025.

HCW Biologics

Risk-Adjusted Performance

6 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in HCW Biologics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, HCW Biologics sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Lipella Pharmaceuticals and HCW Biologics

The main advantage of trading using opposite Lipella Pharmaceuticals and HCW Biologics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lipella Pharmaceuticals position performs unexpectedly, HCW Biologics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HCW Biologics will offset losses from the drop in HCW Biologics' long position.

The idea behind Lipella Pharmaceuticals Common and HCW Biologics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.